Abstract: An object having a surface that has: filaments having a length of from 30 to 6000 ?m, a diameter to length ratio of from 1:10 to 1:20, and are bound to the surface with at least one front face thereof; wherein the distance between two neighboring filaments on the surface is such that the ratio of such distance to the length of the filaments is from 1:3 to 1:10; the filaments have an elasticity of from 104 to 1010 N/m2; the surface of the filament is at least partially hydrophobic, so that the contact angle between a filament and water is greater than 100°, characterized in that the filaments are structurally or chemically anisotropic.

Abstract: The invention relates to a process for cultivating undifferentiated stem cells in suspension and in particular to a method for cultivating stem cells on microcarriers in vessels. The method enables stem cells to be cultivated in a scalable process for the first time, without losing their pluripotentiality. Different types of vessels are suitable for cultivation, such as e.g. spinners and bioreactors. The option of precisely setting the cultivation conditions in said vessels aids the process of obtaining a pluripotentiality of the stem cells. the inventive method also permits large yields of stem cells of an unvarying quality to be produced.

Abstract: The present invention relates to novel P2Y12 receptor antagonists useful for treating, alleviating and/or preventing diseases and disorders related to P2Y12 receptor function as well as pharmaceutical compositions comprising such compounds and methods for preparing such compounds. The present invention is further directed to the use of these compounds, alone or in combination with other therapeutic agents, for the alleviation, prevention and/or treatment of diseases and disorders, especially the use as antithrombotic agents for inhibiting platelet aggregation.

Abstract: The present invention provides ectonucleotidase inhibitors represented by the following formula, including ecto-nucleotide triphosphate diphosphohydrolase (NTPDase) inhibitors and ecto-5?-nucleotidase (ecto-5?-NT) inhibitors, namely nucleotide mimetics as selective NTPDase or ecto-5?-NT inhibitors. It also provides methods for preparations of said compounds. Furthermore provided are pharmaceutical and diagnostic compositions comprising said compounds, and the use of said compounds in a medicament for treating diseases associated with ectonucleotidase activity and/or P1 or P2 receptors.

Abstract: A method is provided, comprising administering at least one guanylhydrazone or salt thereof or a combination thereof to a subject to prevent or ameliorate in said subject at least one of postoperative intestinal inflammation, postoperative ileus, ischemia reperfusion injury, or a combination thereof.

Abstract: The invention relates to compounds selected from among the group comprising general formulas (1), (2), (3), and/or (4) and/or the enantiomers, diastereomers, and derivatives thereof, and the pharmaceutically acceptable salts thereof for producing a medicament used for therapeutically and/or preventively treating disease and pathological conditions linked to regulation of the insulin and/or insulin-like growth factor (IGF) signalling pathway and/or for chemically inducing longevity.

Abstract: A phosphorylated A2A receptor agonist providing agonist properties on the A2A receptor after dephosphorylation the phosphorylated A2A receptor agonist comprises a ribosyl moiety and a purine moiety and being phosphorylated at the 5?-position of the ribose moiety except adenosine monophosphate (AMP), adenosine diphosphate (ADP) or adenosine triphosphate (ATP), a medicament containing the compound of the invention including ADP and the use of the compound of the invention including ATP and ADP for several medical indications e. g. inflammatory events. In particular, compounds of formula (I) are also disclosed.

Abstract: The invention relates to drugs and the use thereof, wherein said drugs contain compounds selected from a group comprising general formulas (1), (2), (3) and (4) and/or enantiomers, diastereomers or the pharmaceutically acceptable salts thereof. Said drugs are used for treating autoimmune and tumoral diseases and/or for immunosuppresion.

Abstract: A medicament containing a compound of the following formulas (Ia) and (Ib): wherein Z is selected from the group consisting of a covalent bond, at least one at least divalent hetero atom, a saturated, unsaturated, branched, unbranched and/or cyclic, substituted or unsubstituted hydrocarbon chain, a saturated or unsaturated, branched, unbranched and/or cyclic, substituted or unsubstituted hydrocarbon chain provided with hetero atoms in the chain thereof, or combinations thereof; R?1 to R?4 and R?1 to R?5 independently represent H, at least one hetero atom, especially oxygen, nitrogen or halogens, a saturated, unsaturated, branched, unbranched and/or cyclic, substituted or unsubstituted hydrocarbon chain, a saturated or unsaturated, branched, unbranched and/or cyclic, substituted or unsubstituted hydrocarbon chain provided with hetero atoms in the chain thereof, or combinations thereof; the two cyclopentadienyl rings are optionally linked together via any of residues R?1 to R?5; R1 and R2 independently r

Abstract: The invention relates to a process for cultivating undifferentiated stem cells in suspension and in particular to a method for cultivating stem cells on microcarriers in vessels. The method enables stem cells to be cultivated in a scalable process for the first time, without losing their pluripotentiality. Different types of vessels are suitable for cultivation, such as e.g. spinners and bioreactors. The option of precisely setting the cultivation conditions in said vessels aids the process of obtaining a pluripotentiality of the stem cells. the inventive method also permits large yields of stem cells of an unvarying quality to be produced.